| ISIN | CH0113817123 |
|---|---|
| Valor Number | 11381712 |
| Bloomberg Global ID | BBG0017T9CY3 |
| Fund Name | Bellevue Biotech DT CHF |
| Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
| Fund Provider | Bellevue Asset Management AG |
| Representative in Switzerland | |
| Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Switzerland |
| Issuing Condition | Special conditions apply to the issue of units |
| Redemption Condition | Special conditions apply to the redemption of units |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 3,910.90 CHF | 23.10.2025 |
|---|---|---|
| Previous Price * | 3,916.44 CHF | 22.10.2025 |
| 52 Week High * | 3,963.66 CHF | 20.10.2025 |
| 52 Week Low * | 3,036.56 CHF | 10.04.2025 |
| NAV * | 3,910.90 CHF | 23.10.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 20,681,174 | |
| Unit/Share Assets *** | 4,105,959 | |
| Trading Information SIX | ||
| YTD Performance | +8.25% |
31.12.2024 - 23.10.2025
31.12.2024 23.10.2025 |
|---|---|---|
| 1 month | +7.31% |
23.09.2025 - 23.10.2025
23.09.2025 23.10.2025 |
| 3 months | +12.07% |
23.07.2025 - 23.10.2025
23.07.2025 23.10.2025 |
| 6 months | +19.39% |
23.04.2025 - 23.10.2025
23.04.2025 23.10.2025 |
| 1 year | +5.61% |
23.10.2024 - 23.10.2025
23.10.2024 23.10.2025 |
| 2 years | +27.59% |
23.10.2023 - 23.10.2025
23.10.2023 23.10.2025 |
| 3 years | +3.87% |
24.10.2022 - 23.10.2025
24.10.2022 23.10.2025 |
| 5 years | +9.42% |
23.10.2020 - 23.10.2025
23.10.2020 23.10.2025 |
| Equity Participation Rate in % | 84.14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | 16.6695 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | 23.10.2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gilead Sciences Inc | 7.54% | |
|---|---|---|
| Amgen Inc | 7.05% | |
| Regeneron Pharmaceuticals Inc | 6.88% | |
| Vertex Pharmaceuticals Inc | 6.50% | |
| Alnylam Pharmaceuticals Inc | 6.35% | |
| AstraZeneca PLC ADR | 6.04% | |
| Insmed Inc | 3.34% | |
| argenx SE ADR | 2.61% | |
| Ionis Pharmaceuticals Inc | 2.07% | |
| Biogen Inc | 1.99% | |
| Last data update | 31.08.2025 | |
| TER | 1.22% |
|---|---|
| TER date | 30.09.2024 |
| Performance Fee *** | 10.00% |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| SRRI date *** | 30.09.2025 |